Non-Intoxicating Cannabinoids Show Promise for Gut Pain in Preclinical Research

Non-intoxicating cannabinoids (niCBs) show potential to normalize intestinal motility, reduce inflammation, and produce analgesic effects in preclinical models of visceral pain. Many of these effects are not mediated through classical CB1/CB2 receptors but rather through TRP channels and voltage-gated ion channels. Evidence also suggests niCBs can be combined for enhanced potency (entourage effect).

Review of preclinical data on non-intoxicating cannabinoids in the treatment of abdominal pain, with focus on non-CB receptor mechanisms of action. Covers multiple niCBs beyond CBD.

Patients with inflammatory bowel diseases increasingly use cannabis for abdominal pain, but clinical results have been mixed. This review suggests the focus on THC and CBD may be too narrow, and that other non-intoxicating cannabinoids acting through different mechanisms may be more relevant for gut pain.

The cannabis plant produces over 100 cannabinoids, most of which are non-intoxicating. Focusing research on the full spectrum of niCBs and their diverse mechanisms could open new therapeutic approaches for gut pain that avoid the psychoactive effects of THC.

Review is limited to preclinical data; human clinical evidence for most niCBs in visceral pain is lacking. Animal models of gut pain may not fully translate to human inflammatory bowel disease. The entourage effect concept among niCBs needs rigorous clinical validation.